PT - JOURNAL ARTICLE AU - Cowling, Benjamin J. AU - Cheng, Samuel M. S. AU - Martín-Sánchez, Mario AU - Au, Niki Y. M. AU - Chan, Karl C. K. AU - Li, John K. C. AU - Luk, Leo L. H. AU - Tsang, Leo C. H. AU - Ip, Dennis K. M. AU - Poon, Leo L. M. AU - Leung, Gabriel M. AU - Peiris, J. S. Malik AU - Leung, Nancy H. L. TI - Slow waning of antibodies following a third dose of BNT162b2 in adults who had previously received two doses of inactivated vaccine AID - 10.1101/2022.07.18.22277741 DP - 2022 Jan 01 TA - medRxiv PG - 2022.07.18.22277741 4099 - http://medrxiv.org/content/early/2022/07/18/2022.07.18.22277741.short 4100 - http://medrxiv.org/content/early/2022/07/18/2022.07.18.22277741.full AB - Introduction Third doses of COVID-19 vaccination provide an important boost to immunity, reducing the risk of symptomatic infection and the risk of severe disease. Third doses have been particularly important for improving protection against variants. However, waning of clinical protection particularly against Omicron has been noted after receipt of third doses.Methods We administered BNT162b2 as a third dose to adults aged ≥30 years who had previously received two doses of inactivated vaccination. We collected blood before the third dose and again after one month and six months, and tested sera using a spike receptor binding domain IgG enzyme-linked immunosorbent assay, a surrogate virus neutralization test, and live virus plaque reduction neutralization assay against ancestral virus and Omicron BA.2.Results We administered BNT162b2 as a third dose to 314 adults. We found robust antibody responses to the ancestral strain at six months after receipt of BNT162b2. Antibody responses to Omicron BA.2 were weaker after the third dose and had declined to a low level by six months. From a small number of participants we observed that natural infection or a fourth dose of vaccination generated similar antibody levels against ancestral virus, but infection generated higher antibody level against Omicron BA.2 than vaccination, suggesting a potential advantage in the breadth of antibody response from hybrid immunity.Conclusions While antibody levels against the ancestral strain remained robust at six months after the third dose, antibody levels against Omicron BA.2 had fallen to low levels suggesting the potential benefits of a fourth dose.Competing Interest StatementBJC consults for AstraZeneca, Fosun Pharma, GlaxoSmithKline, Moderna, Pfizer, Roche and Sanofi Pasteur. BJC has received research funding from Fosun Pharma. The authors report no other potential conflicts of interest.Clinical TrialThe study is registered on Clinicaltrials.gov (NCT05057182).Funding StatementThis project was supported by the Theme-based Research Scheme T11-705/21-N of the Research Grants Council of the Hong Kong Special Administrative Region, China (BJC). BJC is supported by a RGC Senior Research Fellow Scheme grant (HKU SRFS2021-7S03) from the Research Grants Council of the Hong Kong Special Administrative Region, China. The funding bodies had no role in the design of the study, the collection, analysis, and interpretation of data, or writing of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Institutional Review Board of the University of Hong Kong.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors